Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
出版年份 2021 全文链接
标题
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
作者
关键词
-
出版物
Cancers
Volume 13, Issue 17, Pages 4480
出版商
MDPI AG
发表日期
2021-09-06
DOI
10.3390/cancers13174480
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- COVID-19: time to flatten the infodemic curve
- (2021) Anastasios Tentolouris et al. CLINICAL AND EXPERIMENTAL MEDICINE
- First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff
- (2021) Radhika Gharpure et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
- (2021) Saman Saadat et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
- (2021) Ioannis V. Kostopoulos et al. Microorganisms
- Age‐dependent and gender‐dependent antibody responses against SARS‐CoV ‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine
- (2021) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- SARS-CoV-2 Antibody Kinetics Eight Months from COVID-19 Οnset: Persistence of Spike Antibodies but Loss of Neutralizing Antibodies in 24% of Convalescent Plasma Donors
- (2021) Evangelos Terpos et al. European Journal of Internal Medicine
- Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review
- (2021) Eleni Korompoki et al. JOURNAL OF INFECTION
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization
- (2021) Eleni Korompoki et al. JAMA Oncology
- Comparison of neutralizing antibody responses against SARS‐CoV ‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
- (2021) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
- (2021) Evangelos Terpos et al. Journal of Hematology & Oncology
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
- (2021) Dami A. Collier et al. NATURE
- The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
- (2021) Evangelos Terpos et al. Blood Cancer Journal
- Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
- (2021) Evangelos Terpos et al. Cells
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
- (2020) M.L. Solodky et al. ANNALS OF ONCOLOGY
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
- (2020) Kunyu Yang et al. LANCET ONCOLOGY
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
- (2020) Evangelos Terpos et al. LEUKEMIA
- Cancer immunoediting and immune dysregulation in multiple myeloma
- (2020) Kyohei Nakamura et al. BLOOD
- Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience
- (2020) Anthony R. Mato et al. BLOOD
- Organ-specific manifestations of COVID-19 infection
- (2020) Maria Gavriatopoulou et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Are all patients with cancer at heightened risk for severe Coronavirus Disease 2019 (COVID-19)?
- (2020) Georgios Chamilos et al. CLINICAL INFECTIOUS DISEASES
- Low prevalence of IgG antibodies to SARS‐CoV ‐2 in cancer patients with COVID ‐19
- (2020) Tao Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
- (2020) Francesca Romana Mauro et al. LEUKEMIA
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- (2020) Lydia Scarfò et al. LEUKEMIA
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
- (2020) Nina Le Bert et al. NATURE
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2
- (2020) Antonio Marra et al. ANNALS OF ONCOLOGY
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
- (2020) Heinz Ludwig et al. LEUKEMIA
- Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
- (2020) Lindsey E. Roeker et al. LEUKEMIA
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
- (2020) Abi Vijenthira et al. BLOOD
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
- (2020) Christopher Pleyer et al. BLOOD
- Controversies in the use of new bone‐modifying therapies in multiple myeloma
- (2020) Evangelos Terpos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
- (2018) Tilly Varughese et al. CLINICAL INFECTIOUS DISEASES
- Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
- (2018) Tobias Svensson et al. VACCINE
- Ibrutinib may impair serological responses to influenza vaccination
- (2017) Abby P. Douglas et al. HAEMATOLOGICA
- A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia
- (2017) Tamar Tadmor et al. Expert Review of Hematology
- Ibrutinib may impair serological responses to influenza vaccination
- (2017) Abby P. Douglas et al. HAEMATOLOGICA
- Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
- (2016) Clare Sun et al. JAMA Oncology
- How I treat Waldenstrom macroglobulinemia
- (2015) S. P. Treon BLOOD
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) C. Sun et al. BLOOD
- Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
- (2011) O. E. Yri et al. BLOOD
- Immunological mechanisms of vaccination
- (2011) Bali Pulendran et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now